Global Small Molecule Protein Degradation Agent Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Small Molecule Protein Degradation Agent Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Small Molecule Protein Degradation Agent report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Small Molecule Protein Degradation Agent market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Oncology Treatment and Cancer Treatment are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Small Molecule Protein Degradation Agent industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Small Molecule Protein Degradation Agent key manufacturers include BMS, Monte Rosa Therapeutics, Nurix, Novartis, Eisai, Boehringer Ingelheim, Proxygen, Merck Sharp & Dohme and Arvinas, etc. BMS, Monte Rosa Therapeutics, Nurix are top 3 players and held % sales share in total in 2022.
Small Molecule Protein Degradation Agent can be divided into Molecular Gel Degrader and Protein Degradation Targets Chimeras, etc. Molecular Gel Degrader is the mainstream product in the market, accounting for % sales share globally in 2022.
Small Molecule Protein Degradation Agent is widely used in various fields, such as Oncology Treatment, Cancer Treatment, Treatment Of Neurodegenerative Diseases and Other, etc. Oncology Treatment provides greatest supports to the Small Molecule Protein Degradation Agent industry development. In 2022, global % sales of Small Molecule Protein Degradation Agent went into Oncology Treatment filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Small Molecule Protein Degradation Agent market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
BMS
Monte Rosa Therapeutics
Nurix
Novartis
Eisai
Boehringer Ingelheim
Proxygen
Merck Sharp & Dohme
Arvinas
Amgen
Shanghai Meizhi Pharmaceutical
Fendi Technology
Five-Membered Creatures
Gluetacs Therapeutics
Hengrui Medicine
Degron Therapeutics
Segment by Type
Molecular Gel Degrader
Protein Degradation Targets Chimeras
Oncology Treatment
Cancer Treatment
Treatment Of Neurodegenerative Diseases
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Small Molecule Protein Degradation Agent market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Small Molecule Protein Degradation Agent, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Small Molecule Protein Degradation Agent industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Small Molecule Protein Degradation Agent in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Small Molecule Protein Degradation Agent introduction, etc. Small Molecule Protein Degradation Agent Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Small Molecule Protein Degradation Agent market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for Small Molecule Protein Degradation Agent industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Small Molecule Protein Degradation Agent key manufacturers include BMS, Monte Rosa Therapeutics, Nurix, Novartis, Eisai, Boehringer Ingelheim, Proxygen, Merck Sharp & Dohme and Arvinas, etc. BMS, Monte Rosa Therapeutics, Nurix are top 3 players and held % sales share in total in 2022.
Small Molecule Protein Degradation Agent can be divided into Molecular Gel Degrader and Protein Degradation Targets Chimeras, etc. Molecular Gel Degrader is the mainstream product in the market, accounting for % sales share globally in 2022.
Small Molecule Protein Degradation Agent is widely used in various fields, such as Oncology Treatment, Cancer Treatment, Treatment Of Neurodegenerative Diseases and Other, etc. Oncology Treatment provides greatest supports to the Small Molecule Protein Degradation Agent industry development. In 2022, global % sales of Small Molecule Protein Degradation Agent went into Oncology Treatment filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Small Molecule Protein Degradation Agent market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
BMS
Monte Rosa Therapeutics
Nurix
Novartis
Eisai
Boehringer Ingelheim
Proxygen
Merck Sharp & Dohme
Arvinas
Amgen
Shanghai Meizhi Pharmaceutical
Fendi Technology
Five-Membered Creatures
Gluetacs Therapeutics
Hengrui Medicine
Degron Therapeutics
Segment by Type
Molecular Gel Degrader
Protein Degradation Targets Chimeras
Segment by Application
Oncology Treatment
Cancer Treatment
Treatment Of Neurodegenerative Diseases
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Small Molecule Protein Degradation Agent market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Small Molecule Protein Degradation Agent, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Small Molecule Protein Degradation Agent industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Small Molecule Protein Degradation Agent in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Small Molecule Protein Degradation Agent introduction, etc. Small Molecule Protein Degradation Agent Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Small Molecule Protein Degradation Agent market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.